New Drug Approvals: June 2005

Date of Approval: June 10, 2005

Company: Aventis Pasteur Limited

Treatment for: Tetanus Prophylaxis, Diphtheria Prophylaxis, Pertussis Prophylaxis

Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)) is indicated for active booster immunization for the prevention of tetanus, diphtheria and pertussis as a single dose in persons 11 through 64 years of age.

Date of Approval: June 15, 2005

Company: Wyeth Pharmaceuticals

Treatment for: Skin and Structure Infection, Intraabdominal Infection, Pneumonia

Tygacil (tigecycline) is a glycylcycline antibacterial indicated for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections and community-acquired bacterial pneumonia in adults.

Date of Approval: June 16, 2005

Company: Novo Nordisk Inc.

Treatment for: Diabetes Mellitus Type I, Diabetes Mellitus Type II

Levemir (insulin detemir) is a novel, long- acting form of insulin that provides up to a 24-hour duration of action for the treatment of diabetes mellitus (type 1 and type 2).

Date of Approval: June 22, 2005

Company: Boehringer Ingelheim

Treatment for: HIV Infection

Aptivus (tipranavir) is a non-peptidic protease inhibitor which is co-administered with ritonavir for the treatment of HIV Infection.

Date of Approval: June 23, 2005

Company: NitroMed, Inc.

Treatment for: Congestive Heart Failure

BiDil is a fixed-dose combination of isosorbide dinitrate (a vasodilator) and hydralazine hydrochloride (an arterial dilator) indicated for the treatment of heart failure in black patients.

Date of Approval: June 22, 2005

Company: Boehringer Ingelheim

Treatment for: HIV Infection

Aptivus (tipranavir) is a non-peptidic protease inhibitor which is co-administered with ritonavir for the treatment of HIV Infection.

New Dosage Form Approved: June 23, 2008

New Indication Approved: March 20, 2009